Business
Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update
First patients enrolled in study in Cognitive Impairment Associated with Schizophrenia (CIAS) Patient screening underway in study in Alzheimer’s disease with
About this update from Cyclerion Therapeutics, Inc.
[{"type":"text","content":"First patients enrolled in study in Cognitive Impairment Associated with Schizophrenia (CIAS) Patient screening underway in study in Alzheimer’s disease with vascular pathology (ADv) Enrollment ongoing in study in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS); Topline clinical results expected in H1 2022 CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, reported today results for the third quarter 2021 and provided general corporate and pipeline updates. “Cyclerion has made pipeline progress with three ongoing clinical studies related to CY6463, our lead investigational candidate. CY6463 development program is supported by completed clinical studies including a translational pharmacology study that demonstrated efficient entry into the brain and positive effects on multiple measures of brain neurophysiology associated with cognition. Our strategy is to pursue small concurrent signal-seeking studies to evaluate CY6463 in multiple CNS diseases where effective treatment options are lacking today. We plan to review the clinical data from our ongoing exploratory studies to determine how to optimally advance to later stages of development,” said Peter Hecht, Ph.D., Chief Executive Officer of Cyclerion. “We are pleased to have recently initiated enrollment in our CY6463 clinical study in patients with Cognitive Impairment Associated with Schizophrenia (CIAS), a debilitating aspect of schizophrenia that affects over two million patients in the U.S. alone. There is a tremendous societal need for new treatment options for schizophrenia, especially for its cognitive aspects. In addition, we’ve continued to make progress with our clinical studies in Alzheimer’s disease with vascular pathology (ADv) and Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). We believe that CY6463 has the potential to provide a much-needed new treatment option for each of these serious diseases that affect cognition, and we intend to aggressively advance each of our ongoing development studies and evaluate the data” said Cheryl Gault, Chief Operating Officer of Cyclerion. Recent Program and Business Updates Cyclerion continues to develop C...